Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients
EGFR/BRAF/MEK triple-targeted therapy is an effective and safe approach for treating <i>EGFR</i>-mutated NSCLC patients resistant to EGFR-TKIs with acquired <i>BRAF</i> V600E mutations.
Authors
- Ke-Jun Liu (ORCID: https://orcid.org/0000-0001-5770-7865)
- Junwei Su (ORCID: https://orcid.org/0000-0001-7154-8928)
- Ze-Xin Chen
- Chengzhi Zhou (ORCID: https://orcid.org/0000-0003-0029-6879)
- Jin Shi (ORCID: https://orcid.org/0000-0002-1677-791X)
- Yufa Li (ORCID: https://orcid.org/0000-0002-7386-3064)
- Yanying Li (ORCID: https://orcid.org/0000-0001-5580-5111)
- Ke-Jing Tang
- Huajun Chen (ORCID: https://orcid.org/0000-0001-5496-7442)
- Yihui Yao
- Cheng-Di Weng
- Jin−Ji Yang
Institutions
- Sun Yat-sen University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Dongguan People’s Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tlcr-24-358
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- European Society for Medical Oncology